When to intubate in GCS?

GCS ≤ 8 requires intubation for airway protection. The patient cannot protect their own airway at this level of consciousness. Motor score is the most prognostically important component.

What is the best initial fluid for sepsis resuscitation?

Lactated Ringer's (LR) is the preferred resuscitation fluid. The SMART trial (2018) showed balanced crystalloids reduced death, new renal failure, and persistent renal dysfunction compared to normal saline.

When to start vasopressors in septic shock?

Start norepinephrine (first-line vasopressor) if MAP remains < 65 mmHg after initial 30 mL/kg crystalloid resuscitation, or earlier if patient is profoundly hypotensive. Do not delay pressors to complete full fluid resuscitation.

Why can serum uric acid be normal during acute gout?

During acute inflammation, IL-6 increases renal urate excretion and redistributes urate from plasma to tissues. Up to 40% of acute gout flares have normal serum uric acid. Joint aspiration with polarized microscopy is needed for definitive diagnosis.

How do you distinguish lupus flare from infection in SLE?

Key clues: CRP is low/normal in flare but elevated in infection. Complement (C3/C4) drops in flare but is normal/elevated in infection. Procalcitonin is elevated in bacterial infection but normal in flare. Anti-dsDNA rises in flare, stable in infection.

What is the difference between DKA and HHS?

DKA features acidosis (pH 600), hyperosmolality (> 320), and minimal ketosis -typically in Type 2 DM. DKA requires insulin drip; HHS requires aggressive fluid resuscitation first.

When to give tPA in acute ischemic stroke?

IV alteplase (tPA) can be given within 4.5 hours of last known well time in eligible patients. CT head must rule out hemorrhage first. For large vessel occlusion, mechanical thrombectomy can be performed up to 24 hours with favorable imaging.

What antibiotics for community-acquired pneumonia?

Inpatient non-ICU: ceftriaxone + azithromycin. ICU: ceftriaxone + azithromycin (add vancomycin if MRSA risk). Outpatient healthy: amoxicillin. Outpatient with comorbidities: augmentin + azithromycin or respiratory fluoroquinolone. Duration: 5 days if clinically stable for 48 hours.

How to interpret iron studies?

Iron deficiency: low ferritin (< 30), high TIBC, low iron, low transferrin saturation (< 20%). Anemia of chronic disease: normal/high ferritin (acute phase reactant), low TIBC, low iron. A ferritin of 50-100 in an inflamed patient may still represent iron deficiency.

What is the correction rate for hyponatremia?

Correct sodium no more than 8 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS). For symptomatic severe hyponatremia with seizures, give 3% hypertonic saline 100-150 mL bolus over 10-20 minutes. If overcorrected, use D5W + DDAVP rescue protocol.

When to start antibiotics in meningitis?

Within 30-60 minutes. Do NOT delay antibiotics for LP or CT. Draw blood cultures, start empiric antibiotics (vancomycin + ceftriaxone ± ampicillin if > 50 or immunocompromised), then perform LP when possible. Dexamethasone should be given before or with the first antibiotic dose.

DOACs vs warfarin in antiphospholipid syndrome?

DOACs are contraindicated in APS. The TRAPS trial (2018) showed rivaroxaban was inferior to warfarin with more thrombotic events in triple-positive APS patients. Warfarin with INR target 2-3 is the standard for APS, indefinitely.

How to manage scleroderma renal crisis?

ACE inhibitors (captopril) are life-saving -start immediately and titrate aggressively. Do NOT hold for rising creatinine. Steroids > 15 mg prednisone per day precipitate scleroderma renal crisis. ARBs are NOT a substitute -evidence is only for ACEi.

What are the 4 pillars of heart failure treatment?

Guideline-directed medical therapy (GDMT) for HFrEF: (1) ARNI or ACEi/ARB, (2) beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated to target doses.

RoundsRx

Dashboard

Overview

Recent

Rotations

Quick Reference

Antibiotic Guide Analgesia Guide Sedation Guide Bowel Regimen Electrolyte Replacement Pain Management & Conversions Drug Interactions Anticoag Reversal IV Fluid Guide Inotropes Guide Vasopressors Insulin Guide Code Blue & Rapid Response Procedures Guide ECG Interpretation Lab Interpretation Radiology Quick Ref GCS Pocket Card Admission Orders & I-PASS Landmark Trials

Tools

💎 Clinical Pearls 🧠 Pimp Me Quiz 🧮 Clinical Calculators 📰 What's New 🎓 Intern Survival Guide ✅ Rounding Checklists 🩺 Procedure Guides ⚡ Electrolyte Replacement 💧 IV Fluids Guide 🩸 Transfusion Guide 💓 ECG Pattern Guide 🧪 Lab Interpretation Guide 📱 QR Poster 🔗 Resources 🎙️ Channels & Podcasts 🎮 Medical Games 🏛️ Famous Cases 🎬 Media Library

ℹ️ About

Available offline

PulmonologyChronic

Interstitial Lung Disease

A heterogeneous group of diseases causing inflammation and/or fibrosis of the lung parenchyma. IPF is the most common and most lethal. HRCT pattern recognition is essential -UIP vs NSIP vs organizing pneumonia drives management.

🔍 Overview

Common ILD Patterns on HRCT

HRCT Pattern	Key Features	Most Likely Diagnosis	Prognosis
UIP (Usual Interstitial Pneumonia)	Basal, peripheral, subpleural honeycombing + traction bronchiectasis + reticulation. Heterogeneous (areas of normal lung adjacent to fibrosis).	IPF (if no identifiable cause)	Worst. Median survival 3–5 years.
NSIP (Non-Specific Interstitial Pneumonia)	Ground-glass opacities, basal-predominant, relatively uniform. Subpleural sparing. Less honeycombing.	CTD-ILD (RA, scleroderma), drug-induced, idiopathic NSIP	Better than UIP. Often responds to immunosuppression.
Organizing Pneumonia (OP)	Peripheral, patchy consolidations that may be migratory. "Reverse halo" (atoll sign).	COP (cryptogenic), drug-induced, post-infection, CTD	Good. Usually responds dramatically to steroids.
Upper-lobe predominant	Fibrosis/nodules in upper lobes	Sarcoidosis, hypersensitivity pneumonitis (chronic), silicosis, coal workers	Variable

IPF (Idiopathic Pulmonary Fibrosis)

Most common IIP. Male > female. Typically age > 60. Smoking is a risk factor.
Clinical: progressive exertional dyspnea, dry cough, bibasilar Velcro-like crackles on auscultation, clubbing (~50%)
PFTs: restrictive pattern (↓ FVC, ↓ TLC) + ↓↓ DLCO
Diagnosis: UIP pattern on HRCT in appropriate clinical context → may not need biopsy. If HRCT indeterminate → surgical lung biopsy via VATS for confirmation.

Sarcoidosis

Pirfenidone (Esbriet)

ANTIFIBROTIC

ASCEND, 2014

Slows progression, does not cure.

Nintedanib (Ofev)

ANTIFIBROTIC

INPULSIS, 2014

Tyrosine kinase inhibitor.

When to Refer for Transplant

FVC decline ≥ 10% in 6 months
DLCO < 40% predicted
Desaturation < 88% on 6-minute walk test
Hospitalization for respiratory decline or pneumothorax
Refer early -transplant evaluation takes months

💊 Management

IPF -Antifibrotic Therapy

Steroids and immunosuppressants are HARMFUL in IPF. PANTHER-IPF, 2012: prednisone + azathioprine + NAC increased mortality and hospitalizations vs placebo. Stopped early for harm.

Drug	Dose	Evidence	Notes
Pirfenidone (Esbriet) ANTIFIBROTIC	267 mg TID → titrate to 801 mg TID	ASCEND, 2014: reduced FVC decline by ~50% at 1 year.	Slows progression, does not cure. GI side effects (nausea), photosensitivity. Take with food.
Nintedanib (Ofev) ANTIFIBROTIC	150 mg BID	INPULSIS, 2014: reduced FVC decline by ~50%. Also approved for SSc-ILD and progressive fibrosing ILD.	Tyrosine kinase inhibitor. Diarrhea is the main side effect (~60%). Hepatotoxicity -monitor LFTs.

When to Refer for Transplant

FVC decline ≥ 10% in 6 months
DLCO < 40% predicted
Desaturation < 88% on 6-minute walk test
Hospitalization for respiratory decline or pneumothorax
Refer early -transplant evaluation takes months

📋 On Rounds

Why are steroids harmful in IPF?

IPF is a fibrotic process, not primarily inflammatory. The pathology is aberrant wound healing -repeated epithelial injury → fibroblast proliferation → collagen deposition. Steroids suppress the immune system but don't target fibrosis. PANTHER-IPF, 2012 showed that the triple combination of prednisone + azathioprine + NAC increased mortality by 8× and hospitalizations by 4× compared to placebo.

How do you distinguish UIP from NSIP on HRCT, and why does it matter?

This is one of the most important radiographic distinctions in pulmonology because it determines treatment and prognosis. UIP (usual interstitial pneumonia) = IPF pattern: basal-predominant, peripheral honeycombing, traction bronchiectasis, minimal GGO. Prognosis: median survival 3–5 years. Treatment: antifibrotics only (nintedanib or pirfenidone) -steroids are HARMFUL. NSIP (nonspecific interstitial pneumonia)

When should you refer an ILD patient for lung transplant evaluation?

Refer early -don't wait until the patient is too sick. General criteria: (1) FVC declining > 5-10% per year despite treatment (antifibrotics for IPF, immunosuppression for NSIP/CTD-ILD), (2) DLCO < 40% predicted, (3) O₂ requirement at rest or with exertion, (4) 6-minute walk distance < 250m or declining, (5) Pulmonary hypertension (RVSP > 40 on echo).

What is the role of pulmonary rehabilitation in ILD?

Pulmonary rehab is one of the most effective interventions in ILD -yet it's dramatically underutilized. Benefits: improved exercise capacity (6MWD increases 30-50m), reduced dyspnea, improved quality of life, reduced anxiety/depression. It works even in IPF where the lung disease itself is progressive and irreversible -pulmonary rehab trains the muscles and cardiovascular system to work more efficiently with less lung function.

Clinical Examples

📋 Case 1, Idiopathic Pulmonary Fibrosis (IPF)

Patient: 72M with progressive dyspnea × 2 years and dry cough. Bibasilar velcro crackles. PFTs: FVC 58%, DLCO 42% (restrictive + impaired gas exchange). HRCT: basal-predominant honeycombing, traction bronchiectasis, minimal GGO. UIP pattern.

Key findings: Definite UIP pattern on HRCT = IPF diagnosis without biopsy needed (if clinical context fits). IPF is the most common and most lethal ILD, median survival 3-5 years from diagnosis.

Management:

Antifibrotic therapy: pirfenidone or nintedanib (slows FVC decline by ~50%) ASCEND/INPULSIS, 2014
Pulmonary rehabilitation (improves exercise capacity and QOL even as disease progresses)
Supplemental O₂ for resting SpO₂ < 88% or exertional desaturation
Lung transplant evaluation if age < 70, no major comorbidities, refer EARLY (waitlist mortality is high)
NO steroids or immunosuppression (PANTHER-IPF showed HARM from prednisone + azathioprine + NAC in IPF)

Teaching point: Steroids are HARMFUL in IPF, this is the one ILD where immunosuppression makes things worse. Antifibrotics (pirfenidone, nintedanib) slow progression but do not reverse fibrosis. Early transplant referral is critical.

📋 Case 2, Hypersensitivity Pneumonitis (Chronic)

Patient: 55F bird breeder with progressive dyspnea × 1 year. HRCT: diffuse GGO with mosaic attenuation, air trapping on expiratory images, centrilobular nodules. No honeycombing. PFTs: FVC 68%, DLCO 52%. BAL: lymphocytosis 48%.

Key findings: Chronic hypersensitivity pneumonitis from avian antigen exposure. HRCT pattern: GGO + mosaic attenuation + air trapping is classic. BAL lymphocytosis (> 30%) supports the diagnosis. Unlike IPF, HP is potentially reversible with antigen avoidance.

Management:

Antigen avoidance is the MOST important intervention, remove birds, professional home cleaning
Prednisone 0.5 mg/kg daily × 4-8 weeks for symptomatic disease, then slow taper
If fibrotic HP refractory to steroids: mycophenolate or azathioprine as steroid-sparing agents
If fibrotic HP progressing despite antigen avoidance + immunosuppression: consider antifibrotic (nintedanib approved for progressive fibrosing ILD)
Serial PFTs q3-6 months to monitor for progression vs stabilization

Teaching point: HP is the treatable mimic of IPF. The key differentiators: HP has GGO + mosaic attenuation (not honeycombing), BAL lymphocytosis, and an identifiable exposure. Antigen removal can halt or reverse disease if caught before fibrosis.

📋 Case 3, Acute Exacerbation of IPF

Patient: 68M with known IPF on nintedanib. Admitted with acute worsening dyspnea × 5 days. SpO₂ 78% on 6L NC. CT: new bilateral GGO superimposed on known UIP pattern. No PE on CTA. Sputum cultures negative.

Key findings: Acute exacerbation of IPF: rapid respiratory deterioration + new bilateral GGO on CT + no identifiable cause (ruled out infection, PE, HF). Mortality > 50% per episode.

Management:

High-dose methylprednisolone 1g IV daily × 3 days → prednisone 1 mg/kg taper (limited evidence but standard practice)
Broad-spectrum antibiotics until infection excluded (empiric coverage while cultures pending)
High-flow nasal cannula or NIV for respiratory support, intubation carries very poor prognosis in IPF
Discuss goals of care early, in-hospital mortality for intubated IPF patients exceeds 80%
Continue antifibrotic therapy if able to take PO

Teaching point: Acute exacerbation of IPF is often fatal. The most important conversation is goals of care, mechanical ventilation in IPF rarely leads to meaningful recovery. Palliative care should be involved early if the patient does not respond to steroids within 48-72h.

📣 Sample Presentation

One-Liner

"Mrs. Park is a 68-year-old non-smoker presenting with 18 months of progressive dyspnea and dry cough. HRCT shows basal-predominant honeycombing, traction bronchiectasis, and minimal GGO -UIP pattern. PFTs: FVC 62%, DLCO 48%. Consistent with IPF."

Key Points to Cover on Rounds

HRCT: definite UIP pattern (basal honeycombing, traction bronchiectasis, no GGO). PFTs: restrictive (FVC 62%), DLCO 48% (severely reduced). Autoimmune workup: ANA, RF, CCP, myositis panel -all negative (not CTD-ILD). No significant exposures (no birds, mold, medications). Diagnosis: IPF (definite UIP on imaging, exclusion of other causes -biopsy not needed). Treatment: nintedanib 150 mg BID started (antifibrotic -slows FVC decline). NOT steroids (harmful in IPF). O₂: prescribed for exertional desaturation (SpO₂ 84% on 6MWT). Pulmonary rehab referral. Transplant evaluation: referred given age and severity. Plan: PFTs q6 months, annual HRCT.

🧪 Workup

Workup

See the Overview and Management tabs for the ILD workup algorithm (HRCT pattern recognition, PFTs with DLCO, serologic panel for CTD-ILD, bronchoscopy/BAL + surgical lung biopsy when pattern is ambiguous).

💊 Medications

Medications

Medication details (antifibrotics like pirfenidone/nintedanib for IPF, corticosteroids + mycophenolate/azathioprine for CTD-ILD, specific agents by ILD subtype) are in the Management tab with evidence-based dosing and trial citations.

⚡ Summary

Summary

IPF

UIP pattern on HRCT (basal honeycombing, traction bronchiectasis). Antifibrotics only (nintedanib or pirfenidone). NO steroids [PANTHER-IPF harm]. Transplant referral early.

NSIP

GGO-predominant on HRCT. Often associated with CTD (especially scleroderma). Responds to immunosuppression (mycophenolate + steroids). Better prognosis than IPF.

COP

Organizing pneumonia: migratory infiltrates, responds dramatically to steroids. Relapses common → slow taper over months.

CTD-ILD

ILD from autoimmune disease (RA, scleroderma, SLE, myositis). Screen all new ILD for CTD (ANA, RF, CCP, myositis panel). Treat underlying autoimmune disease.

Monitoring

PFTs (FVC, DLCO) q6 months. HRCT annually or with symptoms. 6MWT. Refer for transplant: FVC declining > 5-10%/year, DLCO < 40%, O₂ requirement.

Pulmonary Rehab

Improves exercise capacity, dyspnea, QOL even in progressive disease. Refer early, don't wait for O₂ dependence. Combine with antifibrotics for maximum benefit.

📄 One Pager

Pulmonology · One Pager

Interstitial Lung Disease

CT pattern determines treatment: UIP/honeycombing = antifibrotics (NOT steroids). GGO/NSIP = immunosuppression. Screen all new ILD for CTD. Transplant referral early for IPF.

🧪 IPF

Definite UIP on HRCT (basal honeycombing, traction bronchiectasis, no GGO). Antifibrotics: nintedanib or pirfenidone (slow FVC decline). NO steroids [PANTHER-IPF = harm]. Transplant referral at diagnosis.

🚨 Other ILDs

NSIP: GGO-predominant, often CTD-associated. Responds to steroids + mycophenolate. COP: migratory infiltrates, responds dramatically to steroids. CTD-ILD: treat underlying autoimmune disease.

💊 Monitoring + Referral

PFTs (FVC, DLCO) q6 months. HRCT annually. 6MWT. Pulmonary rehab (improves QOL even in progressive disease). Transplant if: FVC declining > 5-10%/year, DLCO < 40%, O₂ requirement.

💊 Key Drugs

Nintedanib150 mg BID (IPF)

Pirfenidone801 mg TID (IPF)

Mycophenolate2-3g/day (NSIP/CTD-ILD)

Prednisone0.5-1 mg/kg (COP, NSIP)

⚠️ Pitfalls

Steroids for IPF (harmful -worsens outcomes [PANTHER-IPF])
Not screening for CTD (ANA, RF, CCP, myositis panel) in new ILD
Late transplant referral (IPF median survival 3-5 years)
Forgetting pulmonary rehab (dramatically improves QOL)